EA201100078A1 - DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS - Google Patents

DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS

Info

Publication number
EA201100078A1
EA201100078A1 EA201100078A EA201100078A EA201100078A1 EA 201100078 A1 EA201100078 A1 EA 201100078A1 EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A EA201100078 A EA 201100078A EA 201100078 A1 EA201100078 A1 EA 201100078A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
pyrimidine
kinase inhibitors
pyrimidine derivatives
igf
Prior art date
Application number
EA201100078A
Other languages
Russian (ru)
Inventor
Томас Х Марсилье, III
Вэньшу Лу
Бэй Чэнь
Сяосюй Хэ
Сончунь Цзян
Куньйон Ян
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201100078A1 publication Critical patent/EA201100078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

В заявке описаны новые производные пиримидина и содержащие их фармацевтические композиции и способы применения таких соединений. Например, производные пиримидина, предлагаемые в настоящем изобретении, можно применять для лечения, облегчения протекания или предупреждения патологического состояния, которое реагирует на ингибирование инсулиноподобного фактора роста (IGF-1R) или киназы анапластической лимфомы (ALK).The application describes new pyrimidine derivatives and pharmaceutical compositions containing them and methods of using such compounds. For example, the pyrimidine derivatives of the present invention can be used to treat, alleviate, or prevent a pathological condition that responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK).

EA201100078A 2008-06-25 2009-06-24 DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS EA201100078A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7558308P 2008-06-25 2008-06-25
PCT/US2009/048509 WO2009158431A2 (en) 2008-06-25 2009-06-24 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
EA201100078A1 true EA201100078A1 (en) 2011-08-30

Family

ID=41076758

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100078A EA201100078A1 (en) 2008-06-25 2009-06-24 DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS

Country Status (11)

Country Link
EP (1) EP2331526A2 (en)
JP (1) JP2011526291A (en)
KR (1) KR20110020940A (en)
CN (1) CN102203083A (en)
AU (1) AU2009262198B2 (en)
BR (1) BRPI0914545A2 (en)
CA (1) CA2729546A1 (en)
EA (1) EA201100078A1 (en)
MX (1) MX2010014568A (en)
UA (1) UA101057C2 (en)
WO (1) WO2009158431A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP2013522215A (en) 2010-03-09 2013-06-13 オーエスアイ・ファーマシューティカルズ，エルエルシー Combined anticancer therapy
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
ES2628438T3 (en) * 2011-11-29 2017-08-02 Genentech, Inc. Aminopyrimidine derivatives as modulators of LRRK2
WO2014071832A1 (en) 2012-11-06 2014-05-15 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
KR102334260B1 (en) * 2013-03-14 2021-12-02 스미토모 다이니폰 파마 온콜로지, 인크. Jak2 and alk2 inhibitors and methods for their use
AU2015266453C1 (en) * 2014-05-30 2018-09-13 Shanghai Emerald Wellcares Pharmaceutical Co., Ltd Alk kinase inhibitor, and preparation method and use thereof
EP3523289A1 (en) * 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN107488148A (en) * 2017-06-26 2017-12-19 安徽省黄淮兽药有限公司 A kind of hydrocinnamamide insecticides and preparation method thereof
MX2020006587A (en) 2017-12-22 2020-12-10 Ravenna Pharmaceuticals Inc Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors.
TW202045008A (en) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-substituted isoxazole/isoxazoline (hetero) arylamidine compounds, preparation and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003026664A1 (en) * 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
PT1656372E (en) * 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE506953T1 (en) * 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
CA2590110C (en) * 2004-12-30 2014-06-03 Exelixis, Inc. Kinase modulators and method of use
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN101616895A (en) * 2006-12-08 2009-12-30 Irm责任有限公司 Compound and composition as kinases inhibitor
KR101149295B1 (en) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 Compounds as protein kinase inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2713716A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Also Published As

Publication number Publication date
JP2011526291A (en) 2011-10-06
WO2009158431A3 (en) 2010-03-11
CN102203083A (en) 2011-09-28
AU2009262198B2 (en) 2012-09-27
BRPI0914545A2 (en) 2017-05-23
EP2331526A2 (en) 2011-06-15
WO2009158431A2 (en) 2009-12-30
KR20110020940A (en) 2011-03-03
AU2009262198A1 (en) 2009-12-30
CA2729546A1 (en) 2009-12-30
UA101057C2 (en) 2013-02-25
MX2010014568A (en) 2011-03-29

Similar Documents

Publication Publication Date Title
EA201100077A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
EA201100078A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
MX2010002336A (en) Compounds and compositions as kinase inhibitors.
EA201001597A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA200970557A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201101341A1 (en) KINASE INHIBITIVE COMPOUNDS AND PHARMACEUTICAL COMPOSITION BASED ON THEIR BASIS
EA201001596A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201100687A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
MX2012000711A (en) Pyrrolopyrazine inhibitors of kinases.
NZ711376A (en) Heteroaryl compounds and uses thereof
MX2015011514A (en) Heteroaryl compounds and uses thereof.
EA201100580A1 (en) IMIDAZOPIRIDAZINCARBONITRILE USED AS KINASE INHIBITORS
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200970156A1 (en) PYRDISINOUS DERIVATIVES
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX2011012369A (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors.
EA201491647A1 (en) BASED ON ARILETHER KINAZ INHIBITORS
EA201071224A1 (en) LIMK2 INHIBITORS, COMPOSITIONS CONTAINING THEM, AND METHODS OF THEIR USE
EA201590268A1 (en) ARYLACTAM KINASE INHIBITORS
MX2009012079A (en) Condensed heterocyclic compounds as inhibitors of protein kinases.
MX2009003793A (en) Kinase inhibitors.
TN2010000602A1 (en) Pyrimidine derivatives as kinase inhibitors
CU20100259A7 (en) PIRIMIDINE DERIVATIVES AS QUINASA INHIBITORS
WO2009105238A3 (en) Kinase protein binding inhibitors